A comprehensive review of cancer: CRISPR and its application in lung cancer with a potential in overcoming EGFR mutations

Saamya Yadav 1, * and Poonam Agrawal 2

1 Santa Clara High School, United States of America.
2 Beckman Center for Molecular and Genetic Medicine, School of Medicine, Stanford University, United States of America.
 
Review
International Journal of Science and Research Archive, 2024, 13(01), 3047–3067.
Article DOI: 10.30574/ijsra.2024.13.1.2016
Publication history: 
Received on 13 September 2024; revised on 20 October 2024; accepted on 23 October 2024
 
Abstract: 
As a comprehensive review of cancer, oncogenes, and CRISPR, this review explores the transformative potential of CRISPR technology in combating cancer, particularly focusing on lung cancer and oncogenes. CRISPR’s precision gene-editing capabilities offer a promising avenue for developing more targeted cancer therapies, overcoming the limitations of current treatments such as chemotherapy and radiation, which often fail due to cancer cell heterogeneity and resistance. Additionally, this review proposes the potential use of CRISPR to target specific oncogenes like EGFR and its significant promise for improving treatment outcomes in lung cancer by directly modifying or regulating gene function. This review synthesizes current research, highlighting the integration of CRISPR with other therapeutic modalities to enhance the effectiveness of cancer treatments, delivery systems that improve targeting and minimize off-target effects, and the future directions in CRISPR-mediated lung cancer therapy.
 
Keywords: 
CRISPR; Cancer; Lung Cancer; Targeted Therapy; EGFR
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0